Skip to search formSkip to main contentSkip to account menu

amatuximab

Known as: Anti-Mesothelin Monoclonal Antibody MORAb-009, Immunoglobulin G1, Anti-(mesothelin) (Human-Mouse Monoclonal MORAb-009 Heavy Chain), Disulfide with Human-Mouse Monoclonal MORAb-009 Kappa-Chain, Dimer 
A chimeric IgG1 monoclonal antibody against human mesothelin with potential anti-tumor activity. Amatuximab specifically targets mesothelin, a cell… 
National Institutes of Health

Related topics

Related topics

5 relations
Antibody-Dependent Cellular CytotoxicityT-Cell Activationantigen bindingmesothelin

Broader (1)

MORAb-009 monoclonal antibody

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Abstract 546: Selectively targeting CD47 with bispecific antibody to efficiently eliminate mesothelin-positive solid tumors
The CD47- signal regulatory protein α (SIRPα) axis, originally discovered as a mechanism of self-recognition, has emerged as a… 
2019
2019
Mesothelin-Targeted Agents in Mesothelioma
Mesothelin (MSLN) is a cell surface glycoprotein expressed by mesothelial cells of the pleural, peritoneum, and pericardium. Its… 
2018
2018
The anti-mesothelin monoclonal antibody amatuximab enhances the anti-tumor effect of gemcitabine against mesothelin-high expressing pancreatic cancer cells in a peritoneal metastasis mouse model
Pancreatic cancer often has a very poor prognosis, even after complete resection. The recurrence of hepatic and peritoneal… 
2018
2018
Abstract 2770: Dual-targeting mesothelin/CD47 bispecific antibodies for tumor-directed blockade of CD47 in solid cancer
Mesothelin (MSLN) is a lineage restricted cell surface protein with unknown biological function, expressed at low levels on… 
Review
2017
Review
2017
[Systemic Treatment of Malignant Pleural Mesothelioma].
Malignant pleural mesothelioma(MPM)is a highly aggressive tumor with a poor prognosis and an increasing incidence worldwide. The… 
2017
2017
Immunotherapeutic Approaches to Mesothelioma
Several lines of evidence indicate the activation of a host humoral and cellular response in mesothelioma patients. Tumor cells… 
2016
2016
A randomized, placebo-controlled study of amatuximab in combination with pemetrexed and cisplatin (P/C) as front-line therapy for subjects with malignant pleural mesothelioma (MPM).
TPS8577Background: Mesothelin is highly expressed in epithelioid mesothelioma. Amatuximab is a chimeric monoclonal antibody that… 
2015
2015
Tumor and organ uptake of 64Cu labeled MORAb-009, an anti-mesothelin antibody by PET Imaging and biodistribution studies
2011
2011
Effect of chelator conjugation level and injection dose on tumor and organ uptake of 111In-labeled MORAb-009, an anti-mesothelin antibody.
Highly Cited
1982
Highly Cited
1982
Concomitant induction of the cell surface expression of Ia determinants and accessory cell function by a murine macrophage tumor cell line
This study demonstrates that an uncharacterized soluble factor produced in concanavalin A-induced rat spleen cell suspensions has… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)